HomeSmall Caps
Share

Small caps last week: Forbes ranking, Meta funds Oklo fuel, Ceco posts record orders

Lyudmila Milevskaya

Lyudmila Milevskaya

Shipping company Dorian LPG topped Forbes’ ranking of the most successful U.S. small caps / Photo: Shutterstock.com

Shipping company Dorian LPG topped Forbes’ ranking of the most successful U.S. small caps / Photo: Shutterstock.com

Last week, PepGen shares soared 93% after the biotech released new data on its experimental drug for myotonic dystrophy. Meanwhile, Oklo secured manufacturing capacity for components for its future reactors and disclosed Meta’s first payment toward fuel for its Ohio project, while the management at Ceco Environmental raised its full-year orders guidance. In addition, Forbes named its most successful U.S. small caps of 2026, with shipping company Dorian LPG topping the list. Here are these and other highlights from the small-cap sector for the week of November 9-13 in Oninvest’s roundup.

Dorian LPG tops Forbes annual small-cap ranking

Dorian LPG, which ships propane and butane, took the top spot in Forbes’ ranking of most successful U.S. small-cap companies. After disruptions in the Strait of Hormuz, Dorian LPG has focused on shipments from North America to Asia. Longer voyages tied up ships and pushed freight rates higher. In the quarter ended September 30, Dorian LPG’s average daily rate rose 81% year over year to $96,990. Net income almost quadrupled to $213.9 million, including a $63.6 million gain from the sale of two vessels.

Forbes ranked 100 companies with market capitalizations of $300 million to $5 billion. Among the highest-ranked were payments company PaySign (#2), AI infrastructure provider Penguin Solutions (#5), and medical apparel maker FIGS (#9).

Technogym counts 46 hotels on The World’s 50 Best Hotels 2026 list among its clients / Photo: www.technogym.com

Technogym sales slow in 9m26. Wall St still sees 16% upside in the fitness stock.

PepGen skyrockets on positive trial results

PepGen shares jumped 92.9% on Tuesday to $4.61 apiece. The biotech reported phase II trial results for PGN-EDODM1, an experimental drug for myotonic dystrophy type 1. The inherited disorder makes it difficult for muscles to relax after contracting and causes them to weaken over time.

Mean splicing correction, a measure of how much the treatment corrected faulty RNA processing in muscle, was 46.5% in the six patients who received the drug versus 6.8% in the four who received a placebo. The result was higher than those reported in separate trials of drugs from Novartis and Dyne Therapeutics, according to Leerink Partners analyst Joseph Schwartz. In September, a phase III trial of the Novartis drug missed its primary endpoint.

The next day, PepGen priced an offering of new shares at $5 apiece. The management expects to raise $125 million before expenses and use part of the proceeds to fund further trials of the drug.

Swiss biotech Windward Bio is developing drugs for respiratory diseases / Photo: Shutterstock.com

Windward IPO: Sanofi-backed asthma drugmaker goes public on the Nasdaq

vVardis flagship product is designed to treat early-stage tooth decay in children / Photo: Shutterstock.com

vVardis IPO: Apollo-backed dental tech debuts on the NYSE

Green Thumb posts first loss after four profitable quarters

Cannabis producer and retailer Green Thumb Industries reported its first net loss after four consecutive profitable quarters. Revenue rose 11.3% year over year to $324.4 million in the third quarter. Operating income fell to $25.1 million from $36.7 million a year earlier, though it rose from $20 million in the second quarter. The net loss was $4.8 million versus net income of $23.3 million a year earlier. The year-earlier result benefited from a one-time gain on the sale of intellectual property and a hemp products business.

A Motley Fool analyst sees Green Thumb stock as attractive at a price/sales ratio of around 1.3, citing share buybacks and the potential for sales growth as more states open legal cannabis markets. By the time it reported results, the company had repurchased more than $80 million of its stock year to date. By the columnist’s tally, Green Thumb ranked second among the largest U.S. cannabis retailers by quarterly revenue, behind Curaleaf, which reported $353 million.

Carter’s calls itself North America’s largest retailer of clothing for children / Photo: JHVEPhoto / Shutterstock.com

As consumer outperforms tech, Bridgewater 13F shows three growing consumer bets

Oklo strikes deal for components for future reactors

Shares of Oklo, a developer of compact nuclear power plants, rose 22.7% on November 6 to $23.55 apiece. That day, the company announced an agreement with U.S. Forged Rings to reserve manufacturing capacity for steel components for future Aurora reactors. Initial deliveries are expected in 2030. The agreement runs through 2035 and includes an option to expand capacity.

Oklo reported third-quarter revenue of $1.86 million. In its report, Oklo confirmed that it is developing a nuclear power campus in Ohio with up to 1.2 gigawatts of capacity to supply data centers for Meta, the owner of Facebook and Instagram, Barron’s reports. The management expects the first phase to come online in 2030 at the earliest.

NextNRG designs and maintains standalone power systems, develops energy management software, and supplies electric vehicle charging systems / Photo: Shutterstock.com

Micro-cap energy tech NextNRG rebounds 811% after 93% plunge; faces Nasdaq delisting

Ceco raises 2026 orders guidance

Shares of Ceco Environmental, a supplier of air and water treatment systems and industrial temperature control equipment, rose around 19% on Monday to $52 apiece. Third-quarter revenue was reported up 105% year over year at $404.4 million, and adjusted diluted earnings rose to $0.60 per share from $0.26 per share. Thermon, which Ceco acquired in June, contributed $148.5 million to quarterly revenue.

New orders climbed 234% year over year to $777.6 million, and the order book at quarter-end rose 205% to around $2.19 billion. Data center projects accounted for around 20% of the order book, CEO Todd Gleason said.

Ceco’s management now expects 2026 orders to exceed $2.5 billion. It previously expected at least $2 billion. The management forecasts full-year revenue of $1.300-1.375 billion. In its first revenue outlook for 2027, it projected $2.1-2.3 billion, including a full year of contributions from Thermon.

Share

Trending

Stock Screener
Buy
Sell
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
Small Caps
Investment and Finance News